LEXICON PHARMACEUTICALS, INC.
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) is a biopharmaceutical company headquartered in The Woodlands, Texas with a mission to pioneer medicines that transform patients' lives. The company's website is www.lexpharma.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What LEXICON PHARMACEUTICALS, INC. does
In the company’s own words
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) is a biopharmaceutical company headquartered in The Woodlands, Texas with a mission to pioneer medicines that transform patients' lives. The company's website is www.lexpharma.com.
Lexicon's primary focus is on the research and development of innovative drug candidates and the commercialization of approved therapeutics. The company's lead commercial product is INPEFA (sotagliflozin), an oral tablet approved in the United States in May 2023 to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. Lexicon maintains a small virtual contract sales force for INPEFA and sells primarily through major wholesalers and regional distributors.
The company's clinical pipeline includes sotagliflozin in development for hypertrophic cardiomyopathy, with the Phase 3 SONATA-HCM trial currently enrolling approximately 500 patients. Lexicon is also pursuing regulatory approval of ZYNQUISTA (sotagliflozin) for type 1 diabetes, with ongoing proceedings following complete response letters from the FDA. Pilavapadin, an oral small molecule candidate for neuropathic pain, has completed three Phase 2 clinical trials and received Fast Track designation from the FDA for diabetic peripheral neuropathic pain treatment.
Lexicon has established strategic collaborations with major pharmaceutical companies. In March 2025, the company granted Novo Nordisk an exclusive, worldwide license to develop and commercialize LX9851 for obesity and associated cardiometabolic disorders. In October 2024, Lexicon licensed sotagliflozin to Viatris for development and commercialization outside the United States. The company maintains a long-standing drug discovery alliance with Bristol-Myers Squibb in the neuroscience field, from which pilavapadin originated.
The company does not operate its own manufacturing facilities, instead relying on multiple contract manufacturing organizations for production of INPEFA and clinical supplies of drug candidates. Lexicon was incorporated in Delaware in 1995 and listed on Nasdaq in 2000. The company operates as a smaller reporting company and is classified as a non-accelerated filer.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- THE WOODLANDS, TX
- Fiscal year end
- December
- CIK
- 1062822
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns LEXICON PHARMACEUTICALS, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · LEXICON PHARMACEUTICALS, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do LEXICON PHARMACEUTICALS, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of LEXICON PHARMACEUTICALS, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in LEXICON PHARMACEUTICALS, INC.'s last four quarterly filings that the numbers alone won't show?”